HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/25/2026

1. NVDA
2. SPY
3. AAPL
4. USO
5. XPEV
6. BMO
7. VEEV
8. DKS
9. AMD
10. MU

Go back to HyBryte™ Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment
Soligenix, Inc. (NASDAQ: SNGX) Delayed: 0.41 +0.01 (2.50%)
Previous Close $0.40    52 Week High $4.35 
Open $0.41    52 Week Low $0.44 
Day High $0.41    P/E N/A 
Day Low $0.40    EPS $-0.81 
Volume 213,476